By 2032, the epinephrine auto-injectors market size is projected to grow to US$ 3.2 billion from US$ 2 billion in 2022, with a Compound Annual Growth Rate (CAGR) of 4.9% between 2022 and 2032.
The market for epinephrine auto-injectors is expected to experience positive growth trends in the future. This is due to the significant advancements in syringes and injectors in response to changing clinical and patient needs, resulting in an increased demand for epinephrine auto-injectors.
The opportunities in the epinephrine auto-injectors market are expanding rapidly. The growing prevalence of allergies among individuals has been a major driver of the market’s growth. The increasing number of people with allergies to dust, insect bites and venom, food, and food additives has contributed to the growth of the epinephrine auto-injectors market.
Moreover, vendor investments in research and development initiatives to create chlorofluorocarbon-free epinephrine auto-injector inhalers using hydrofluoroalkanes as propellants have accelerated the key trends and opportunities in the epinephrine auto-injectors market.
For Details on Vendors and Their Offerings – Request A Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14876
However, excessive use of epinephrine can lead to adverse side effects such as cardiac arrhythmia, pulmonary edema, vomiting, and brain hemorrhage, which may pose a challenge for the epinephrine auto-injectors market.
During the forecast period, the regional market for epinephrine auto-injectors is expected to be driven by the increasing number of people suffering from various types of allergies, the availability of low-cost generic epinephrine auto-injectors, and the high adoption rate of epinephrine auto-injectors in the United States. The adoption trends in the epinephrine auto-injector market are also expected to contribute to its growth.
Key takeaways:
- In the United States, the epinephrine auto-injectors market size is estimated to reach US$ 1.2 Billion by 2032, increasing at a CAGR of 4.7% through 2032.
- The epinephrine auto-injectors market share in the United Kingdom is expected to be worth US$ 132.9 Million by 2032, with a CAGR of 3.6% through 2032.
- China’s epinephrine auto-injectors market share is expected to reach US$ 233.7 Million by 2032, with a CAGR of 4.2% through 2032.
- The market share for epinephrine auto-injectors in Japan is expected to be valued US$ 188.5 Million by 2032, expanding at a 3.3% annual rate through 2032.
- South Korea is expected to reach a market size of US$ 117.6 Million in epinephrine auto-injectors by 2032, with a CAGR of 2.8% through 2032.
- The epinephrine auto-injectors market’s Hospitals segment from the end user category is predicted to develop at a CAGR of 4.8% through 2032.
- Through 2032, 0.3 mg sector in the epinephrine auto-injectors market’s dosage category will grow at a CAGR of 4.9%.
Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-14876
Competitive landscape:
New market research report on epinephrine auto-injectors says that Adamis Pharmaceuticals Corporation, Alk-Abello A/S, Impax Laboratories, Inc., Mylan N.V., Antares Pharma is among the legacy player’s vendors.
The research offers a comprehensive competition analysis of these top competitors in the epinephrine auto-injectors market, including epinephrine auto-injectors market growth, epinephrine auto-injectors market share, epinephrine auto-injectors market adoption trends and important market strategies.
Recent Development in the Epinephrine Auto-Injectors:
- Antares Pharma (US) struck an arrangement with Lunatus Global Medical Supplies in August 2020. (Dubai). Antares will deliver packaged goods to Lunatus under this arrangement, and Lunatus will submit and get regulatory permission for XYOSTED in the UAE and Saudi Arabia, as well as promote, market, and distribute XYOSTED in these two countries.
- SHL Medical (Switzerland) bought Weibel CDS in March 2020. (Switzerland). The goal of this purchase was to increase SHL Medical’s capacity to develop more sophisticated medication delivery systems based on human-centered designs and functionality.
- Eli Lilly spent US$ 470 million and generated approximately 460 new jobs in Durham, NC in January 2020. With this extension, North Carolina’s research triangle park gained a new state-of-the-art pharmaceutical production plant.
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/14876
Key Segments:
By End-User:
- Hospitals
- Clinics
- Home Based
- Others
By Dosage:
- 0.15 mg
- 0.3 mg
- Others
By Age Group:
- 0-4 Years
- 5-14 Years
- 15-24 Years
- 25-49 Years
- 50-64 Years
- Above 65 Years
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
